Advanced Cardiovascular — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$25,343	1
2024	Research	$114,374	7
2023	Research	$30,369	18
2022	Research	$175,240	40
2021	Research	$125,481	28
2020	Research	$149,444	27
2019	Research	$188,007	29

Breakdown

Who paid Research payments · program years 2019–2025

CSL Behring $752,488 146 payments
Novartis Pharmaceuticals Corporation $25,343 1 payment
AstraZeneca UK Limited $21,677 1 payment
Alnylam Pharmaceuticals Inc. $8,750 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $564,481 117 payments
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $188,007 29 payments
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) $25,343 1 payment
a phase IIb two cohort,randomised,placebo controlled,double blind,multi centre,dose ranging study of AZD5462 in stable patients with chronic heart failure $21,677 1 payment
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $8,750 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.